Anktiva
(Nogapendekin Alfa)Phase 3Small molecule
This medication is used to treat a specific type of bladder cancer when initial treatment with BCG therapy alone hasn't worked effectively. It works by stimulating the immune system to recognize and attack cancer cells in the bladder.[1] Anktiva is currently being investigated across 2 indications[3], with its most advanced program in Phase 3.[1]
Anktiva is one of 39 small molecule programs targeting Lynch syndrome. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Taxotere
AAvyxa
Phase 3
Trodelvy
GileadPhase 3
Anktiva
SSWOG Cancer Research Network
Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nogapendekin Alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSWOG Cancer Research Network